AbbVie Inc. (NYSE:ABBV) Receives Average Recommendation of "Moderate Buy" from Analysts

Key Points

• Analysts maintain a Moderate Buy consensus on AbbVie, with 19 buy, two strong-buy and five hold ratings. The average 12-month price target is $275.95, above the stock’s reported $260.69 price.
• AbbVie reported quarterly EPS of $3.65 and revenue of $16.99 billion, exceeding analyst estimates, while revenue grew 10.2% year over year. The company reaffirmed 2026 adjusted EPS guidance of $13.87–$14.07.
• Pipeline expansion offers longer-term growth potential: positive Phase 3 results for etentamig and the roughly $10.9 billion Apogee acquisition strengthen AbbVie’s oncology and immunology portfolios, though the acquisition is expected to dilute earnings initially.

Shares of AbbVie Inc. (NYSE:ABBV - Get Free Report) have been given a consensus rating of "Moderate Buy" by the twenty-six ratings firms that are currently covering the firm, MarketBeat.com reports. Five analysts have rated the stock with a hold rating, nineteen have given a buy rating and two have given a strong buy rating to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $275.9545.

ABBV has been the topic of several recent research reports. Citigroup upped their target price on shares of AbbVie from $230.00 to $260.00 and gave the stock a "neutral" rating in a research note on Wednesday, July 15th. BMO Capital Markets raised their price target on shares of AbbVie from $258.00 to $300.00 and gave the company an "outperform" rating in a research report on Monday, July 13th. Cantor Fitzgerald boosted their price target on shares of AbbVie from $265.00 to $285.00 and gave the stock an "overweight" rating in a research note on Monday, August 3rd. BNP Paribas Exane upped their price objective on AbbVie from $218.00 to $247.00 and gave the stock a "neutral" rating in a research report on Tuesday, August 11th. Finally, Canaccord Genuity Group increased their price objective on AbbVie from $282.00 to $290.00 and gave the company a "buy" rating in a research note on Monday, August 3rd.

Insider Transactions at AbbVie

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the sale, the executive vice president owned 74,430 shares of the company's stock, valued at $18,607,500. This trade represents a 30.53% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.06% of the stock is owned by corporate insiders.

Institutional Trading of AbbVie

A number of large investors have recently made changes to their positions in the company. Litman Gregory Wealth Management LLC purchased a new stake in shares of AbbVie in the 4th quarter valued at approximately $28,000. Imprint Wealth LLC lifted its position in shares of AbbVie by 56.2% during the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company's stock worth $29,000 after purchasing an additional 45 shares during the last quarter. Burk Holdings LLC acquired a new position in shares of AbbVie during the second quarter worth $30,000. Legacy Wealth Managment LLC ID grew its stake in shares of AbbVie by 115.9% during the fourth quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company's stock worth $31,000 after purchasing an additional 73 shares in the last quarter. Finally, IFC & Insurance Marketing Inc. purchased a new position in AbbVie in the fourth quarter valued at $31,000. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Etentamig delivers positive Phase 3 results. AbbVie said its CERVINO trial met both primary endpoints in relapsed/refractory multiple myeloma. The treatment produced a 74% objective response rate and reduced the risk of disease progression or death by 60% versus standard therapies. The results support a potential new oncology growth driver and may allow AbbVie to compete for share in the increasingly competitive multiple myeloma market. AbbVie CERVINO Phase 3 results
• Positive Sentiment: Apogee expands AbbVie’s immunology pipeline. AbbVie completed its approximately $10.9 billion acquisition of Apogee Therapeutics, adding late-stage zumilokibart for atopic dermatitis and additional programs targeting asthma and other inflammatory diseases. The deal strengthens AbbVie’s post-Humira growth prospects and diversifies its pipeline. AbbVie completes Apogee acquisition
• Neutral Sentiment: Full-year earnings guidance was reaffirmed. AbbVie maintained adjusted 2026 EPS guidance of $13.87 to $14.07 and third-quarter guidance of $3.84 to $3.88. The range is broadly consistent with expectations, but its midpoint is slightly below the current consensus estimate of $14.02, limiting the immediate upside reaction.
• Negative Sentiment: Acquisition costs create near-term pressure. The Apogee transaction is expected to dilute earnings initially and become accretive only later, reportedly around 2032. Investors may therefore focus on the substantial cash commitment and the long wait before financial benefits fully materialize. AbbVie Apogee acquisition analysis

AbbVie Price Performance

Shares of AbbVie stock opened at $260.69 on Friday. The stock has a market capitalization of $460.58 billion, a price-to-earnings ratio of 73.64, a price-to-earnings-growth ratio of 1.18 and a beta of 0.29. The business has a 50-day moving average of $254.57 and a 200 day moving average of $229.87. AbbVie has a 12 month low of $190.75 and a 12 month high of $267.47.

AbbVie (NYSE:ABBV - Get Free Report) last issued its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. During the same period in the prior year, the firm earned $2.97 earnings per share. The business's revenue for the quarter was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Equities research analysts anticipate that AbbVie will post 14.05 earnings per share for the current year.

AbbVie Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th were issued a dividend of $1.73 per share. The ex-dividend date was Wednesday, July 15th. This represents a $6.92 annualized dividend and a yield of 2.7%. AbbVie's dividend payout ratio is 195.48%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source